Company Profile for 22nd Century Group, Inc.

--(BUSINESS WIRE)--Founded in 1998, 22nd Century Limited, LLC (22nd Century) is a plant biotechnology company whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and breeding. The company owns or exclusively controls 98 issued patents in 79 countries where at least 75% of the world’s smokers reside. 22nd Century is committed to developing and commercializing (i) the world’s most effective and acceptable smoking cessation aid and (ii) for those smokers who refuse to quit smoking, consumer-acceptable modified risk tobacco products that reduce exposure to smoke toxins compared to conventional cigarettes. Through a merger on January 25, 2011, 22nd Century became a wholly-owned subsidiary of 22nd Century Group, Inc. Goodrich Tobacco Company is a subsidiary of 22nd Century.

Company:	22nd Century Group, Inc.
Headquarters Address:	Williamsville, New York
	Williamsville, NY 14221
Main Telephone:	716-270-1523
Website:	www.xxiicentury.com/
Ticker/ISIN:	XXII(OTCBB)/US90137F1030
Type of Organization:	Public
Industry:	Biotechnology
Earnings Release Dates:	1st Quarter: May 25, 2011
	2nd Quarter: August 25, 2011
	3rd Quarter: November 25, 2011
	4th Quarter: March 15, 2012
Key Executives:	CEO: Joseph Pandolfino
	President: Henry Sicignano III
	VP of R&D: Michael Moynihan
CEO
Contact:	Joseph Pandolfino
Phone:	716-270-1523
Email:	[e-mail]
CFO
Contact:	C. Anthony Rider
Phone:	716-270-1523
Email:	[e-mail]